相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1
Emi Kimoto et al.
DRUG METABOLISM AND DISPOSITION (2019)
Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations
Anne M. Filppula et al.
SCIENTIFIC REPORTS (2019)
Liabilities Associated with the Formation of Hard Electrophiles in Reactive Metabolite Trapping Screens
Amit S. Kalgutkar
CHEMICAL RESEARCH IN TOXICOLOGY (2017)
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions
Heidi J. Einolf et al.
DRUG METABOLISM AND DISPOSITION (2017)
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
Peter N. Morcos et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma
Jialin Mao et al.
PHARMACEUTICAL RESEARCH (2016)
Clinical drug interaction profile of idelalisib in healthy subjects
Feng Jin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Inhibitory Effect of Single and Repeated Doses of Nilotinib on the Pharmacokinetics of CYP3A Substrate Midazolam
Hefei Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer
Hilary Calvert et al.
ANTI-CANCER DRUGS (2014)
Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity
Alexandra Carls et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Evaluation of Various Static In Vitro-In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug
Md L. T. Vieiral et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4
Brooke M. Rock et al.
MOLECULAR PHARMACOLOGY (2014)
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers
Catherine Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes
Jialin Mao et al.
DRUG METABOLISM AND DISPOSITION (2013)
Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
Zhengping Wang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Use of High Doses of Quetiapine in Bipolar Disorder Episodes are not Linked to High Activity of Cytochrome P4503A4 and/or Cytochrome P4502D6
Yasser Khazaal et al.
PSYCHIATRIC QUARTERLY (2013)
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
H. M. Jones et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone Intermediate
Joanna E. Barbara et al.
DRUG METABOLISM AND DISPOSITION (2013)
Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin
Varun Garg et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks
Suvi T. M. Orr et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Drug-Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug-Drug Interaction Prediction
Jane R. Kenny et al.
PHARMACEUTICAL RESEARCH (2012)
Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes
Phillip Yates et al.
DRUG METABOLISM AND DISPOSITION (2012)
Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions
Jialin Mao et al.
DRUG METABOLISM AND DISPOSITION (2012)
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study
Keith T. Flaherty et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions
Yuan Chen et al.
DRUG METABOLISM AND DISPOSITION (2011)
CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs
Alfred Zimmerlin et al.
DRUG METABOLISM AND DISPOSITION (2011)
Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma
Jialin Mao et al.
DRUG METABOLISM AND DISPOSITION (2011)
Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir
Brian J. Kirby et al.
DRUG METABOLISM AND DISPOSITION (2011)
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover
K. Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go?
Evan J. Friedman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug Transport Insights from Methadone Interactions with Ritonavir/Indinavir
Evan D. Kharasch et al.
ANESTHESIOLOGY (2009)
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase
David J. Greenblatt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator
Lilly Xu et al.
DRUG METABOLISM AND DISPOSITION (2009)
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
Scott W. Grimm et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers
Makiko Kokudai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Mechanism-based inactivation of human cytochromes P450s: Experimental characterization, reactive intermediates, and clinical implications
Paul F. Hollenberg et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation
Marian Iwamoto et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam
Maria Toth et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Comparison of different approaches to predict metabolic drug-drug interactions
H. J. Einolf
XENOBIOTICA (2007)
Time-dependent inactivation of P450 3A4 by raloxifene: Identification of Cys239 as the site of apoprotein Alkylation
Brian R. Baer et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2007)
Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics
L. Becquemont et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
R. Scott Obach et al.
DRUG METABOLISM AND DISPOSITION (2007)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
RS Obach et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Effect of propiverine on cytochrome p450 enzymes:: A cocktail interaction study in healthy volunteers
D Tomalik-Scharte et al.
DRUG METABOLISM AND DISPOSITION (2005)
Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes
P Zhao et al.
DRUG METABOLISM AND DISPOSITION (2005)
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil
YH Wang et al.
DRUG METABOLISM AND DISPOSITION (2005)
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
M Adams et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo
BJ Ring et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data
CS Cook et al.
XENOBIOTICA (2004)
Atomoxetine hydrochloride: Clinical drug-drug interaction prediction and outcome
JM Sauer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
ED Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs
DJ McConn et al.
DRUG METABOLISM AND DISPOSITION (2004)
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
SG O'Brien et al.
BRITISH JOURNAL OF CANCER (2003)
Effect of mibefradil on CYP3A4 in vivo
ML Veronese et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
M Zdravkovic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
YWF Lam et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics
JF Rogers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol:: Evidence for heme destruction and covalent binding to protein
HL Lin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Lack of interaction between citalopram and the CYP3A4 substrate triazolam
A Nolting et al.
PHARMACOTHERAPY (2000)
分享论文
